Sanofi Meets with FDA Panel on Type 1 Diabetes Med

TIME: 8 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration(FDA) (F.R. Page 61642) holds a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss new drug application 210934 for sotagliflozin oral tablet, sponsored by Sanofi-Aventis U.S. LLC, for the proposed indication: Adjunct to insulin therapy to improve glycemic control in adults with type 1 (T1) diabetes mellitus.

DATE: January 17, 2019

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, Room 1503, Silver Spring, Md.

CONTACT: LaToya Bonner, 301-796-9001, EMDAC@fda.hhs.gov

https://www.marketscreener.com/SANOFI-4698/news/Sanofi-Health-and-Human-Services-Department-HHS-Food-and-Drug-Administration-FDA-F-R-Page-6-27765267/